4 results match your criteria: "University of Paris East Creteil (UPEC)[Affiliation]"
Pract Radiat Oncol
November 2024
Department of Radiation Oncology, Henri Mondor University Hospital, Creteil, France; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955 (i-Biot), University of Paris East Creteil (UPEC), Creteil, France.
The use of neurostimulators has increased in recent decades. However, safety guidelines in patients undergoing radiation therapy (RT) are lacking. We report 2 cases of pelvic RT for prostate cancer in patients with spinal cord neurostimulators.
View Article and Find Full Text PDFPract Radiat Oncol
June 2024
Department of Radiation Oncology, Henri Mondor University Hospital, Créteil, France; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, i-Biot and University of Paris East Créteil (UPEC), Créteil, France.
Ann Chir Plast Esthet
July 2020
Henri-Mondor Breast Center, hôpitaux universitaires Henri-Mondor, 51, avenue Marechal de Lattre de Tassigny, 94010 Créteil, France; Department of Radiation Oncology, hôpitaux universitaires Henri-Mondor, 51, avenue Marechal de Lattre de Tassigny, 94010 Créteil, France; Inserm Unit 955, Team 21, IMRB, Créteil, France; University of Paris East Creteil (UPEC), Créteil, France.
Background And Objective: Quality of life preservation after anti-cancer therapy is a major challenge for breast cancer survivors. Approximately 42-70% of patients who receive systemic therapy for breast cancer, including endocrine therapy, will develop vulvovaginal atrophy (VVA). For these patients, the commonly proposed gel-based treatments for topical applications are restrictive.
View Article and Find Full Text PDFMenopause
October 2018
Department of Maxillofacial and Plastic & Reconstructive Surgery, Henri Mondor University Hospital, Créteil, France.
Objective: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer.
Methods: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of <15 on the Gloria Bachman Vaginal Health Index (VHI) comprised of five items including: vaginal pH, elasticity, fluid volume (secretions), epithelial integrity, and moisture.